Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPO1 inhibitor + BTK inhibitor + high-dose methotrexate for primary central nervous system lymphoma
ChiCTR2200062154Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zanubrutinib, methotrexate and selinexor in primary central nervous system lymphoma (PCNSL), secondary central nervous system lymphoma (SCNSL), mature B-cell lymphoma and 1 more, sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoints: Overall response rate and Complete response rate. Started Jul 2022; status: recruiting.
02
Drugs
zanubrutinibmethotrexateselinexor
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2200062154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062154.